https://crenolanibinhibitor.co....m/bronchoscopic-intr
Additional outcs when it comes to additional outcomes usually supported those of the main analysis. CAR-positive T cells) or certainly one of five standard regimens. The primary end point was progression-free survival. Key secondary end points were overall response (limited reaction or much better) and total success. Safety ended up being assessed. Ide-cel therapy considerably prolonged progression-free survival and improve
Curtir
Comentario
Compartilhar
